DRG Market Assessment reports

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is…

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF/MEK inhibitor…

Chemotherapy remains the cornerstone of colorectal cancer treatment and is prescribed with angiogenesis or EGFR inhibitors in the metastatic setting. The colorectal cancer treatment landscape has…

The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy…

China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…

Immune checkpoint inhibitors have greatly altered the treatment landscape for urothelial carcinoma. Initially confined to advanced disease, the anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo…

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China…

The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…

Immune checkpoint inhibitors, such as Merck & Co.’s Keytruda and GlaxoSmithKline’s Jemperli, and targeted therapies, such as Eisai’s Lenvima, have revolutionized the therapeutic landscape of…

The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…

Metastatic esophageal cancer remains a subpopulation for which few treatment options exist. For decades, treatment was limited to chemotherapy-based regimens such as FOLFOX and DCF, but the recent…